Clinical Trials

OMS-I100 – Phase II Metastatic Melanoma Clinical Trial

Approximately 70,000 new cases of melanoma will be diagnosed every year, and this number is increasing. Despite this cancer being the deadliest form of all skin cancers, there still remains few treatment options for patients with advance stage disease. Previous data from a Phase I study demonstrated that OMS ElectroImmunotherapy in melanoma patients is safe and well-tolerated. In addition, promising therapeutic outcomes were observed with 53% of patients with metastatic disease demonstrating an objective response with this therapy.

A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with late-stage metastatic melanoma (OMS-I100) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 25 patients with advance stage cutaneous, in-transit malignant melanoma.

Enrollment for this clinical trial is currently underway. For further information about this trial, Click Here

OMS-I110 – Phase II Merkel Cell Carcinoma Clinical Trial

Merkel cell carcinoma is a rare, but deadly disease. With a mortality rate of 40%, treatment options for these patients remain scarce, and recurrence following standard therapy is high. Because 80% of Merkel cell carcinomas are caused by an associated viral infection (Merkel cell polyomavirus), it is believed that an efficient and targeted immunotherapy may be a potential therapeutic approach for this disease.

A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with local and metastatic Merkel cell carcinoma (OMS-I110) is being conducted in collaboration with the University of Washington. This open-label, multi-center Phase II trial will enroll approximately 15 patients with Merkel cell carcinoma.

Enrollment for this clinical trial is currently underway. For further information about this trial, Click Here.

OMS-I120 – Phase II Cutaneous T-Cell Lymphoma Clinical Trial

Cutaneous t-cell lymphoma is a rare form of non-Hodgkin’s lymphoma that affects T-cells of the immune system, resulting in immune dysfunction. Though not life-threatening, there remains few treatment options for this disease with current therapies not demonstrating long-term benefits. Because this is a disease of the immune system, it is believed that immunotherapy has the potential to provide safe and long-term benefits for this disease.

A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with early and late stage cutaneous t-cell lymphoma (OMS-I120) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 27 patients with cutaneous T-cell lymphoma.

Enrollment for this clinical trial is expected to initiate before the end of 2011.